Frédéric Revah

Frédéric Revah Ph.D. is since 2010, Chief Executive Officer of Genethon, a not-for-profit R&D organization dedicated to developing gene therapy treatments for rare diseases, from research to clinical development. He has been until mid-2021 President of YposKesi, one EU’s largest industrial platforms for GMP-manufacturing of gene therapy products created in Nov. 2016 as a spin-off from Genethon with the support of BPI-France. He is also Chairman of the Board of Atamyo, spin-off biotech from Genethon dedicated to developing gene therapies for neuromuscular diseases. Previous to joining Genethon, Frédéric Revah had a long-standing experience in pharmaceutical industry, as well as in biotech companies, both publicly-traded and private, where he held several corporate managerial positions. He has also been advisor for life-science VC funds and member of the Comité National de la Recherche Scientifique. He started his career as an academic researcher in the field of Neuroscience, being a tenure scientist at the Institut Pasteur (Paris).
He obtained his Ph.D. at the Institut Pasteur / Université Paris V, and graduated from the Ecole Polytechnique engineering school.